High level of circulat ing microparticles in patients with BCR/
ABL negative myeloproliferative neoplasm - A pilot study

J 2019

High level of circulat ing microparticles in patients with BCR/ ABL negative myeloproliferative neoplasm - A pilot study

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Lucie ŘÍHOVÁ, Jiřina ZAVŘELOVÁ, Petra OVESNÁ et. al.

Základní údaje

Originální název

High level of circulat ing microparticles in patients with BCR/ ABL negative myeloproliferative neoplasm - A pilot study

Autoři

ASWAD, Mohamed Hussam (760 Sýrie, garant, domácí), Jarmila KISSOVÁ (203 Česká republika, domácí), Lucie ŘÍHOVÁ (203 Česká republika, domácí), Jiřina ZAVŘELOVÁ (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika, domácí) a Miroslav PENKA (203 Česká republika, domácí)

Vydání

Klinická onkologie, Brno, Ambit Media a.s. 2019, 0862-495X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/19:00112977

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.14735/amko2019109

Klíčová slova anglicky

Janus Kinase 2; microparticles; myeloproliferative disorders; procoagulation activity; thrombosis

Štítky

rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 18. 2. 2020 07:49, Mgr. Tereza Miškechová

Anotace

V originále

BACKGROUND: Microparticles (MPs) are small (0.1-1 [MU]m) cell-derived vesicles released during activation or apoptosis, with a surface-exposed phosphatidylserine along with antigens indicating the cellular origin. The level of MPs is known to be elevated in thromboembolic diseases and malignancies; it is believed that MPs are not only amplifying but can also initiate the thrombogenesis processes. BCR/ABL negative myeloproliferative neoplasms (MPNs) are clonal haematopoietic diseases, which include polycythemia vera, essential thrombocythemia and primary myelofibrosis. One of the main problems of MPN patients is high risk and incidence of thrombosis which affect the survival, quality of life and life expectancy. PATIENTS AND METHODS: The clinical significance of circulating MPs was assessed in a group of 179 patients with BCR/ABL-negative MPNs. Analysis of MPs was done using flow cytometry on 417 samples, and MPs procoagulation activity was performed using a functional assay called Zymuphen MP-activity (Hyphen Biomed, Neuville-sur-oise, France) on 274 samples. RESULTS: Significantly higher absolute and relative count of platelet MPs was found in MPN patients when compared with healthy group, respectively (p = 0.001, p = 0.043). Erythrocyte MPs were also significantly higher in MPN patients than in the healthy group (p < 0.001). Procoagulation activity of MPs was as well significantly higher in patients compared to the control group (p < 0.001). Patients with primary myelofibrosis had decreased absolute and relative count of platelet MPs compared to polycythemia vera and essential thrombocythemia patients, respectively (p = 0.008, p = 0.014). Presence of JAK2V617F mutation was associated with higher absolute and relative count of platelet MPs, respectively (p = 0.045, p = 0.029). CONCLUSION: Although some literature data support the hypothesis of a direct relation between MPs and thrombotic events in MPN patients, further studies are needed to evaluate the clinical implication of MPs in the hypercoagulation state of MPN patients.

Návaznosti

MUNI/A/1105/2018, interní kód MU

Název: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI (Akronym: VýDiTeHeMA VI)

Investor: Masarykova univerzita, Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VI, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Lucie ŘÍHOVÁ, Jiřina ZAVŘELOVÁ, Petra OVESNÁ a Miroslav PENKA. High level of circulat ing microparticles in patients with BCR/ ABL negative myeloproliferative neoplasm - A pilot study. Klinická onkologie. Brno: Ambit Media a.s., 2019, roč. 32, č. 2, s. 109-116. ISSN 0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko2019109.

@article{1623640,
   author = {Aswad, Mohamed Hussam and Kissová, Jarmila and Říhová, Lucie and Zavřelová, Jiřina and Ovesná, Petra and Penka, Miroslav},
   article_location = {Brno},
   article_number = {2},
   doi = {http://dx.doi.org/10.14735/amko2019109},
   keywords = {Janus Kinase 2; microparticles; myeloproliferative disorders; procoagulation activity; thrombosis},
   language = {eng},
   issn = {0862-495X},
   journal = {Klinická onkologie},
   title = {High level of circulat ing microparticles in patients with BCR/ ABL negative myeloproliferative neoplasm - A pilot study},
   url = {http://dx.doi.org/10.14735/amko2019109},
   volume = {32},
   year = {2019}
}

TY  - JOUR
ID  - 1623640
AU  - Aswad, Mohamed Hussam - Kissová, Jarmila - Říhová, Lucie - Zavřelová, Jiřina - Ovesná, Petra - Penka, Miroslav
PY  - 2019
TI  - High level of circulat ing microparticles in patients with BCR/ ABL negative myeloproliferative neoplasm - A pilot study
JF  - Klinická onkologie
VL  - 32
IS  - 2
SP  - 109-116
EP  - 109-116
PB  - Ambit Media a.s.
SN  - 0862495X
KW  - Janus Kinase 2
KW  - microparticles
KW  - myeloproliferative disorders
KW  - procoagulation activity
KW  - thrombosis
UR  - http://dx.doi.org/10.14735/amko2019109
L2  - http://dx.doi.org/10.14735/amko2019109
N2  - BACKGROUND: Microparticles (MPs) are small (0.1-1 [MU]m) cell-derived vesicles released during activation or apoptosis, with a surface-exposed phosphatidylserine along with antigens indicating the cellular origin. The level of MPs is known to be elevated in thromboembolic diseases and malignancies; it is believed that MPs are not only amplifying but can also initiate the thrombogenesis processes. BCR/ABL negative myeloproliferative neoplasms (MPNs) are clonal haematopoietic diseases, which include polycythemia vera, essential thrombocythemia and primary myelofibrosis. One of the main problems of MPN patients is high risk and incidence of thrombosis which affect the survival, quality of life and life expectancy. PATIENTS AND METHODS: The clinical significance of circulating MPs was assessed in a group of 179 patients with BCR/ABL-negative MPNs. Analysis of MPs was done using flow cytometry on 417 samples, and MPs procoagulation activity was performed using a functional assay called Zymuphen MP-activity (Hyphen Biomed, Neuville-sur-oise, France) on 274 samples. RESULTS: Significantly higher absolute and relative count of platelet MPs was found in MPN patients when compared with healthy group, respectively (p = 0.001, p = 0.043). Erythrocyte MPs were also significantly higher in MPN patients than in the healthy group (p < 0.001). Procoagulation activity of MPs was as well significantly higher in patients compared to the control group (p < 0.001). Patients with primary myelofibrosis had decreased absolute and relative count of platelet MPs compared to polycythemia vera and essential thrombocythemia patients, respectively (p = 0.008, p = 0.014). Presence of JAK2V617F mutation was associated with higher absolute and relative count of platelet MPs, respectively (p = 0.045, p = 0.029). CONCLUSION: Although some literature data support the hypothesis of a direct relation between MPs and thrombotic events in MPN patients, further studies are needed to evaluate the clinical implication of MPs in the hypercoagulation state of MPN patients.
ER  -

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Lucie ŘÍHOVÁ, Jiřina ZAVŘELOVÁ, Petra OVESNÁ a Miroslav PENKA. High level of circulat ing microparticles in patients with BCR/ ABL negative myeloproliferative neoplasm - A pilot study. \textit{Klinická onkologie}. Brno: Ambit Media a.s., 2019, roč.~32, č.~2, s.~109-116. ISSN~0862-495X. Dostupné z: https://dx.doi.org/10.14735/amko2019109.

Podrobný výpis o publikaci